DERM Insider Trading

Insider Ownership Percentage: 19.42%
Insider Buying (Last 12 Months): $169,300.00
Insider Selling (Last 12 Months): $9,187.50

Journey Medical Insider Trading History Chart

This chart shows the insider buying and selling history at Journey Medical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Journey Medical Share Price & Price History

Current Price: $3.85
Price Change: Price Increase of +0.25 (6.94%)
As of 05/29/2024 01:00 AM ET

This chart shows the closing price history over time for DERM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Journey Medical Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/25/2024Lindsay A Md RosenwaldDirectorBuy10,000$3.04$30,400.00144,245View SEC Filing Icon  
3/22/2024Claude MaraouiCEOBuy10,000$3.48$34,800.002,163,430View SEC Filing Icon  
3/22/2024Justin Adam SmithDirectorBuy30,000$3.47$104,100.00134,717View SEC Filing Icon  
2/22/2024Joseph BeneschCFOSell2,450$3.75$9,187.5060,710View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Journey Medical (NASDAQ:DERM)

7.25% of Journey Medical stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Journey Medical Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/14/2024Heron Bay Capital Management33,669$0.12M0.0%N/A0.169%Search for SEC Filing on Google Icon
5/10/2024Acadian Asset Management LLC222,663$0.82M0.0%+687.5%1.117%Search for SEC Filing on Google Icon
5/10/2024Perkins Capital Management Inc.22,000$81K0.1%-31.3%0.110%Search for SEC Filing on Google Icon
5/10/2024Nwam LLC11,820$41K0.0%N/A0.059%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Journey Medical logo
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
Read More on Journey Medical

Today's Range

Now: $3.85
Low: $3.50
High: $4.07

50 Day Range

MA: $3.65
Low: $2.92
High: $4.42

52 Week Range

Now: $3.85
Low: $1.11
High: $8.11


245,508 shs

Average Volume

161,971 shs

Market Capitalization

$77.05 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Journey Medical?

Journey Medical's top insider shareholders include:
  1. Claude Maraoui (CEO)
  2. Lindsay A Md Rosenwald (Director)
  3. Justin Adam Smith (Director)
  4. Joseph Benesch (CFO)
Learn More about top insider investors at Journey Medical.

Who are the major institutional investors of Journey Medical?

Journey Medical's top institutional shareholders include:
  1. Acadian Asset Management LLC — 1.12%
  2. Heron Bay Capital Management — 0.17%
  3. Perkins Capital Management Inc. — 0.11%
  4. Nwam LLC — 0.06%
Learn More about top institutional investors of Journey Medical stock.

Which major investors are selling Journey Medical stock?

Within the previous quarter, DERM stock was sold by these institutional investors:
  1. Perkins Capital Management Inc.

Which major investors are buying Journey Medical stock?

In the last quarter, DERM stock was acquired by institutional investors including:
  1. Acadian Asset Management LLC
  2. Heron Bay Capital Management
  3. Nwam LLC
Within the previous year, these company insiders have bought Journey Medical stock:
  1. Claude Maraoui (CEO)
  2. Lindsay A Md Rosenwald (Director)
  3. Justin Adam Smith (Director)
Learn More investors buying Journey Medical stock.